Ignite Creation Date:
2025-12-24 @ 10:10 PM
Ignite Modification Date:
2026-01-02 @ 2:42 AM
Study NCT ID:
NCT05207735
Status:
UNKNOWN
Last Update Posted:
2022-01-26
First Post:
2021-11-24
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
PD-1 Inhibitor Sintilimab Combined With Capecitabine for Adjuvant Treatment After Radical Resection of Cholangiocarcinoma.
Sponsor:
Henan Cancer Hospital
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-01
Start Date Type:
ESTIMATED
Primary Completion Date:
2023-12
Primary Completion Date Type:
ESTIMATED
Completion Date:
2024-12
Completion Date Type:
ESTIMATED
First Submit Date:
2021-11-24
First Submit QC Date:
None
Study First Post Date:
2022-01-26
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-01-12
Last Update Post Date:
2022-01-26
Last Update Post Date Type:
ACTUAL